Decreased Ebola Transmission after Rapid Response to Outbreaks in Remote Areas, Liberia, 2014
Kim A. Lindblade
, Francis Kateh, Thomas K. Nagbe, John C. Neatherlin, Satish K. Pillai, Kathleen R. Attfield, Emmanuel Dweh, Danielle T. Barradas, Seymour G. Williams, David J. Blackley, Hannah L. Kirking, Monita R. Patel, Monica Dea, Mehran S. Massoudi, Kathleen Wannemuehler, Albert E. Barskey, Shauna L. Mettee Zarecki, Moses Fomba, Steven Grube, Lisa Belcher, Laura N. Broyles, T. Nikki Maxwell, Jose E. Hagan, Kristin Yeoman, Matthew Westercamp, Joseph D. Forrester, Joshua Mott, Frank Mahoney, Laurence Slutsker, Kevin M. DeCock, and Tolbert G. Nyenswah
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (K.A. Lindblade, J.C. Neatherlin, S.K. Pillai, K.R. Attfield, D.T. Barradas, S.G. Williams, D.J. Blackley, H.L. Kirking, M.R. Patel, M. Dea, M.S. Massoudi, K. Wannemuehler, A.E. Barskey, S.L. Mettee Zarecki, S. Grube, L. Belcher, L.N. Broyles, T.N. Maxwell, J.E. Hagan, K. Yeoman, M. Westercamp, J. Forrester, J. Mott, F. Mahoney, L. Slutsker, K.M. DeCock); Ministry of Health and Social Welfare, Monrovia, Liberia (F. Kateh, T.K. Nagbe, E. Dweh, M. Fomba, T. Nyenswah)
Main Article
Table 4
Hazard ratios for survival during outbreaks of Ebola virus disease in remote rural areas, Liberia, August–December 2014
Characteristic |
Hazard ratio (95% CI) |
p value |
Sex |
|
0.37 |
F |
0.8 (0.5–1.3) |
|
M
|
Referent
|
|
Age, y |
|
0.27 |
0–14 |
Referent |
|
15–19 |
0.9 (0.2–4.2) |
|
20–29 |
0.8 (0.4–1.8) |
|
30–39 |
0.8 (0.4–1.7) |
|
40–49 |
0.8 (0.3–1.8) |
|
50–59 |
0.5 (0.2–1.9) |
|
>60
|
1.5 (0.7–3.4)
|
|
Ebola treatment unit |
|
0.04 |
No |
Referent |
|
Yes |
0.5 (0.3–0.8) |
|
Main Article
Page created: September 22, 2015
Page updated: September 22, 2015
Page reviewed: September 22, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.